- Home
- DBD vs ETNB Comparison
DBD vs ETNB Comparison
Compare DBD & ETNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DBD
- ETNB
- Stock Information
- Founded
- DBD 1859
- ETNB 2018
- Country
- DBD United States
- ETNB United States
- Employees
- DBD 21000
- ETNB N/A
- Industry
- DBD EDP Services
- ETNB Biotechnology: Pharmaceutical Preparations
- Sector
- DBD Technology
- ETNB Health Care
- Exchange
- DBD Nasdaq
- ETNB Nasdaq
- Market Cap
- DBD 1.9B
- ETNB 1.5B
- IPO Year
- DBD N/A
- ETNB 2019
- Fundamental
- Price
- DBD $55.32
- ETNB $9.86
- Analyst Decision
- DBD Strong Buy
- ETNB Strong Buy
- Analyst Count
- DBD 2
- ETNB 8
- Target Price
- DBD $65.00
- ETNB $26.43
- AVG Volume (30 Days)
- DBD 198.5K
- ETNB 2.3M
- Earning Date
- DBD 08-06-2025
- ETNB 08-04-2025
- Dividend Yield
- DBD N/A
- ETNB N/A
- EPS Growth
- DBD N/A
- ETNB N/A
- EPS
- DBD N/A
- ETNB N/A
- Revenue
- DBD $3,696,800,000.00
- ETNB N/A
- Revenue This Year
- DBD $2.02
- ETNB N/A
- Revenue Next Year
- DBD $1.96
- ETNB N/A
- P/E Ratio
- DBD N/A
- ETNB N/A
- Revenue Growth
- DBD N/A
- ETNB N/A
- 52 Week Low
- DBD $34.38
- ETNB $4.16
- 52 Week High
- DBD $55.43
- ETNB $11.84
- Technical
- Relative Strength Index (RSI)
- DBD 78.20
- ETNB 53.99
- Support Level
- DBD $51.46
- ETNB $9.58
- Resistance Level
- DBD $52.30
- ETNB $10.13
- Average True Range (ATR)
- DBD 1.05
- ETNB 0.52
- MACD
- DBD 0.24
- ETNB -0.12
- Stochastic Oscillator
- DBD 95.79
- ETNB 43.62
About DBD Diebold Nixdorf Incorporated Common stock
Diebold Nixdorf Inc is engaged in providing software and hardware services for financial and retail industries. The customer segments of the company are Banking, which offers integrated solutions for financial institutions, and Retail, which offers solutions, software, and services that improve the checkout process for retailers. A majority of its revenue is generated from the Banking segment. Geographically, the company generates maximum revenue from Europe, Middle East, and Africa (EMEA), followed by the Americas and the Asia-Pacific region.
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).